Macrophage activation syndrome in pediatrics
Alessandra Alongi1, Roberta Naddei2, Laura De Miglio3
1Università degli Studi di Genova, Genoa, Italy.
Summary
Macrophage activation syndrome (MAS), a life-threatening hyperinflammatory condition related to hemophagocytic lymphohistiocytosis (HLH), requires prompt recognition and treatment. New classification criteria for MAS in systemic juvenile idiopathic arthritis (sJIA) have been developed.
Area of Science:
- Rheumatology
- Immunology
- Hematology
Background:
- Macrophage activation syndrome (MAS) is a severe hyperinflammatory complication within the hemophagocytic lymphohistiocytosis (HLH) spectrum.
- It can arise in various autoimmune and rheumatic diseases, presenting a significant clinical challenge.
- MAS involves a dysfunctional immune response, necessitating urgent diagnosis and management due to its potentially fatal course.
Purpose of the Study:
- To introduce a new set of classification criteria for MAS complicating systemic juvenile idiopathic arthritis (sJIA).
- To facilitate earlier and more accurate diagnosis of MAS in this specific patient population.
Main Methods:
- Development of classification criteria through a multinational collaborative effort.
- Focus on identifying key clinical and laboratory features indicative of MAS in sJIA.
Main Results:
- A new set of classification criteria for MAS complicating sJIA has been established.
- These criteria aim to improve diagnostic accuracy and timeliness.
Conclusions:
- Prompt recognition and intervention are critical for managing MAS due to its rapid and severe progression.
- The newly developed classification criteria offer a valuable tool for diagnosing MAS in sJIA patients.
- High-dose parenteral corticosteroids are identified as the primary treatment modality for MAS.
